An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Trial Status: administratively complete
ULTRA-V: Study to Assess the Efficacy and Safety of Ublituximab in Combination with
Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects
with Chronic Lymphocytic Leukemia (CLL)
Inclusion Criteria
Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) that warrants treatment
Adequate organ system function as specified in the protocol
Ability to follow protocol procedures.
Exclusion Criteria
Subjects receiving cancer therapy or any investigational drug within 21 days of Cycle 1, Day 1
Prior exposure to any PI3K inhibitor or venetoclax
Autologous hematologic stem cell transplant within 6 months of study entry. Prior allogeneic hematologic stem cell transplant is excluded
Active Hepatitis B or Hepatitis C.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03801525.
Locations matching your search criteria
United States
Georgia
Atlanta
Emory University Hospital/Winship Cancer Institute
